A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

Short Bowel Syndrome (SBS) Clinical Trial

Official title:
A Non-interventional, Multicentre Retrospective Study of the Effectiveness and Safety of Teduglutide (REVESTIVE®) in Short Bowel Syndrome Patients in Canada

Status Recruiting

Clinical Trial Summary

The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in Canada. This study is about collecting existing data only; participants receive teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. No new information will be collected during this study. The study will be conducted using data from the Takeda OnePath Patient Support Program (PSP) or Takeda Global Pharmacovigilance.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05371028
Study type	Observational
Source	Takeda
Contact	Takeda Contact
Phone	+1-877-825-3327
Email	medinfoUS@takeda.com
Status	Recruiting
Phase
Start date	September 23, 2023
Completion date	July 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01674478` - Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies	Phase 2
Completed	`NCT05113082` - Retrospective Study on Participants With Short Bowel Syndrome and Chronic Intestinal Failure That Underwent Transplantation in Brazil
Recruiting	`NCT05561647` - A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using GATTEX